Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | SCD5 | Q86SK9 | 2/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.35 |
| ▸ | SCD | O00767 | 1/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5122491 | 1.00 | CYP1A2 (0.41) | CYP1A2POLBCYP3A4CYP2C19USP30 | |
| SCHEMBL5119061 | 1.00 | CYP1A2 (0.41) | CYP1A2POLBCYP3A4CYP2C19USP30 | |
| SCHEMBL5130041 | 0.89 | UCHL1 (0.43) | USP30HCRTR2GPR119SCD5HDAC6 | |
| SCHEMBL5115026 | 0.89 | UCHL1 (0.43) | USP30HCRTR2GPR119SCD5HDAC6 | |
| SCHEMBL5115001 | 0.86 | USP30 (0.38) | USP30HCRTR2GPR119SCD5HDAC6 | |
| SCHEMBL5123655 | 0.86 | HDAC6 (0.38) | USP30HCRTR2GPR119SCD5HDAC6 | |
| SCHEMBL5173319 | 0.86 | USP30 (0.38) | USP30HCRTR2GPR119SCD5HDAC6 | |
| SCHEMBL4908872 | 0.85 | USP30 (0.44) | USP30HCRTR2GPR119SCD5NR1H2 | |
| SCHEMBL4918972 | 0.85 | USP30 (0.44) | USP30HCRTR2GPR119SCD5NR1H2 | |
| SCHEMBL3859454 | 0.84 | SCD5 (0.48) | POLBUSP30HCRTR2GPR119SCD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080161330-A1 | Pyrimidines as Igf-I Inhibitors | ASTRAZENECA AB (SE) | 2008-07-03 | — | — | US | disclosed |
| EP-1869028-A1 | PYRIMIDINES AS IGF-I INHIBITORS | AstraZeneca AB (SE) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006106306-A1 | PYRIMIDINES AS IGF-I INHIBITORS | ASTRAZENECA AB (SE) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161330-A1 | Pyrimidines as Igf-I Inhibitors | IGF1R, IGFBP1, IGFBP2 | CYP1A2 3097/4885POLB 185/4885CYP3A4 3991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.